J
James A. Martenson
Researcher at Mayo Clinic
Publications - 143
Citations - 14827
James A. Martenson is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Radiation therapy & Colorectal cancer. The author has an hindex of 43, co-authored 142 publications receiving 13872 citations. Previous affiliations of James A. Martenson include University of Washington & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
John S. Macdonald,Stephen R. Smalley,Jacqueline Benedetti,Scott A. Hundahl,Norman C. Estes,Grant N. Stemmermann,Daniel G. Haller,Jaffer A. Ajani,Leonard L. Gunderson,J. Milburn Jessup,James A. Martenson +10 more
TL;DR: This investigation investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction.
Journal ArticleDOI
Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.
Jay S. Cooper,Matthew D. Guo,Arnold Herskovic,John S. Macdonald,James A. Martenson,Muhyi Al-Sarraf,Roger W. Byhardt,Anthony H. Russell,Jonathan J. Beitler,Sharon A. Spencer,Sucha O. Asbell,Mary V. Graham,Lawrence L. Leichman +12 more
TL;DR: Combined therapy increases the survival of patients who have squamous cell or adenocarcinoma of the esophagus, T1-3 N0-1 M0, compared with RT alone, and severe acute toxic effects also were greater in the combined therapy groups.
Journal ArticleDOI
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
Bruce D. Minsky,Thomas F. Pajak,Robert J. Ginsberg,Thomas M. Pisansky,James A. Martenson,Ritsuko Komaki,Gordon Okawara,Seth A. Rosenthal,David P. Kelsen +8 more
TL;DR: Although there was a higher treatment-related mortality rate in the patients assigned to the high-dose radiation arm, it did not seem to be related to the higher radiation dose, and there was no significant difference in median survival, 2-year survival, or local/regional failure and local/Regional persistence of disease.
Journal ArticleDOI
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
Michael J. O'Connell,James A. Martenson,Harry S. Wieand,James E. Krook,John S. Macdonald,Daniel G. Haller,Robert J. Mayer,Leonard L. Gunderson,Tyvin A. Rich +8 more
TL;DR: A protracted infusion of fluorouracil during pelvic irradiation improved the effect of combined-treatment postoperative adjuvant therapy in patients with high-risk rectal cancer.
Journal ArticleDOI
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroœsophageal junction
John S. Macdonald,S. R. Smalley,J. Benedetti,S.A Hundhal,Norman C. Estes,G.N Stemmermannn,D.G Haller,Jaffer A. Ajani,Leonard L. Gunderson,J.M Jessup,James A. Martenson +10 more
TL;DR: Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection.